Bruno Lacarelle
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bruno Lacarelle.
Antimicrobial Agents and Chemotherapy | 2000
Jacques Albanese; Marc Leone; Bernard Bruguerolle; Marie-Laure Ayem; Bruno Lacarelle; Claude Martin
ABSTRACT Cerebrospinal fluid (CSF) penetration and the pharmacokinetics of vancomycin were studied after continuous infusion (50 to 60 mg/kg of body weight/day after a loading dose of 15 mg/kg) in 13 mechanically ventilated patients hospitalized in an intensive care unit. Seven patients were treated for a sensitive bacterial meningitis and the other six patients, who had a severe concomitant neurologic disease with intracranial hypertension, were treated for various infections. Vancomycin CSF penetration was significantly higher (P< 0.05) in the meningitis group (serum/CSF ratio, 48%) than in the other group (serum/CSF ratio, 18%). Vancomycin pharmacokinetic parameters did not differ from those obtained with conventional dosing. No adverse effect was observed, in particular with regard to renal function.
Anesthesiology | 1990
Jacques Albanese; Claude Martin; Bruno Lacarelle; Pierre Saux; Alain Durand; F. Gouin
The pharmacokinetics of propofol were determined in nine patients (seven men, two women, (mean +/- SD) 55.8 +/- 21.2 yr, 65.2 +/- 8 kg) requiring prolonged mechanical ventilation of their lungs. After an initial dose of 1-3 mg/kg, propofol was administered iv at 3 mg/kg/h for 72 h. Arterial blood samples were collected at selected times during and up to 72 h after infusion. Propofol whole blood concentrations were determined by high-performance liquid chromatography with fluorescence detection. Individual pharmacokinetic parameters were estimated by noncompartmental analysis. Derived pharmacokinetic parameters showed a long terminal phase (T1/2 = 1878 +/- 672 min), a large volume of distribution at steady state (Vdss = 1666 +/- 756 l), and a high total body clearance (Cl = 1.57 +/- 0.56 l/min). While the propofol terminal elimination half-life is longer than that previously reported, emergence from sedation after prolonged administration will be governed by both redistribution mechanisms arising from the large distribution volumes and elimination from the body.
Biochemical and Biophysical Research Communications | 2002
Quoc-Binh N'Guyen; Frédérique Fallone; Eric Seree; Frédéric Fina; Pierre-Henri Villard; Nolwen Guigal; Michel De Méo; Bruno Lacarelle; Pierre-Marie Martin; Yves Barra
CYP1A1 is largely involved in carcinogenesis through the bioactivation of numerous procarcinogens. Exposure to environmental pollutants such as polycyclic aromatic hydrocarbons (PAHs) leads to induction of CYP1A1 via AhR pathway. We have previously demonstrated that fetal bovine serum (FBS) induces CYP1A1 gene transcription. In this work, we show evidence that the serum does not contain an AhR ligand and we evaluated the effect of a 3-methylcholanthrene (3-MC) and FBS cotreatment on CYP1A1 expression. CYP1A1 activity was potentiated by this treatment. This potentiation was at least in part associated with an increase of the CYP1A1 mRNA and gene transcription levels. FBS potentiation of CYP1A1 PAH-mediated induction was related to a significant increase of single strand breaks of DNA as compared to a single 3-MC treatment. Moreover, we demonstrated that human serum induces CYP1A1 with a high interindividual variability. The potentiation by serum of polycyclic aromatic hydrocarbon CYP1A1 induction could be involved in the etiology of some human cancers.
Gastroenterology | 2004
Eric Seree; Pierre-Henri Villard; J.-M. Pascussi; T. Pineau; Patrick Maurel; Q.B. Nguyen; Frédérique Fallone; P.-M. Martin; S. Champion; Bruno Lacarelle; Jean-François Savouret; Yves Barra
Biochemical and Biophysical Research Communications | 1994
Pierre-Henri Villard; Eric Seree; Bruno Lacarelle; M.C. Therenefenoglio; Yves Barra; L. Attolini; B. Bruguerole; Alain Durand; J. Catalin
Biochemical and Biophysical Research Communications | 1996
Eric Seree; Pierre-Henri Villard; J.L. Re; M. De Meo; Bruno Lacarelle; Laurence Attolini; G. Duménil; Jacques Catalin; Alain Durand; Yves Barra
Toxicology | 2005
Frédérique Fallone; Pierre-Henri Villard; Laetitia Decome; Eric Seree; Michel De Méo; Christine Chacon; Alain Durand; Yves Barra; Bruno Lacarelle
British Journal of Clinical Pharmacology | 2007
Caroline Solas; Nicolas Simon; Marie-Pierre Drogoul; Sylvie Quaranta; Véronique Frixon-Marin; Véronique Bourgarel-Rey; Corinne Brunet; Jean-Albert Gastaut; Alain Durand; Bruno Lacarelle; Isabelle Poizot-Martin
Toxicology and Applied Pharmacology | 2002
Pierre Henri Villard; Emmanuelle Sampol; Jean L Elkaim; Franck Puyoou; Dominique Casanova; Eric Seree; Alain Durand; Bruno Lacarelle
Biochemical and Biophysical Research Communications | 2004
Frédérique Fallone; Pierre-Henri Villard; Eric Seree; Odile Rimet; Quock Binh Nguyen; Véronique Bourgarel-Rey; Francis Fouchier; Yves Barra; Alain Durand; Bruno Lacarelle